Assessing the Relationship Between Neighborhood Socioeconomic Disadvantage and Telemedicine Use Among Patients With Breast Cancer and Examining Differential Provisions of Oncology Services Between Telehealth and In-Person Visits: Quantitative Study.
Assessing the Relationship Between Neighborhood Socioeconomic Disadvantage and Telemedicine Use Among Patients With Breast Cancer and Examining Differential Provisions of Oncology Services Between Telehealth and In-Person Visits: Quantitative Study. JMIR Cancer. 2024 Jul 18; 10:e55438.
PMID: 39024570
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J Clin Oncol. 2024 Jun 27; JCO2302170.
PMID: 38935923
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. Breast Cancer Res Treat. 2024 Jun 21.
PMID: 38904892
Racial differences in familiarity, interest, and use of integrative medicine among patients with breast cancer.
Racial differences in familiarity, interest, and use of integrative medicine among patients with breast cancer. Breast Cancer Res Treat. 2024 May 15.
PMID: 38748087
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nat Commun. 2024 May 10; 15(1):3957.
PMID: 38730268
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nat Commun. 2024 Mar 27; 15(1):2691.
PMID: 38538574
The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC). Clin Breast Cancer. 2024 Jun; 24(4):263-270.
PMID: 38582617
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
PMID: 38109213
Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer.
Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 2024 Mar; 25(3):269-270.
PMID: 38342112
Racial differences in familiarity, interest, and use of integrative medicine among patients with breast cancer.
Racial differences in familiarity, interest, and use of integrative medicine among patients with breast cancer. Res Sq. 2024 Feb 01.
PMID: 38352451